Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482490 | 0.91 | DRD2 (0.49) | DRD2TBXA2RP2RX3MRGPRX4F10 | |
| SCHEMBL1482646 | 0.91 | DRD2 (0.53) | DRD2TBXA2RP2RX3 | |
| SCHEMBL1482458 | 0.88 | PTGER1 (0.43) | DRD2TBXA2RP2RX3MRGPRX4F10 | |
| SCHEMBL1482892 | 0.88 | KMT2A (0.45) | CCR2PLA2G2AMAPTTHRB | |
| SCHEMBL1482685 | 0.86 | KMT2A (0.48) | MAPT | |
| SCHEMBL1482809 | 0.86 | DRD2 (0.49) | DRD2TBXA2RP2RX3MRGPRX4MAPT | |
| SCHEMBL1482636 | 0.84 | DRD2 (0.52) | DRD2TBXA2RMRGPRX4 | |
| SCHEMBL1482801 | 0.84 | TBXA2R (0.44) | DRD2TBXA2RP2RX3CCR2 | |
| SCHEMBL1482665 | 0.82 | KDM4E (0.47) | DRD2TBXA2RP2RX3CCR2 | |
| SCHEMBL1482850 | 0.82 | GRIN1 (0.48) | MRGPRX4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | DRD2 1464/4885TBXA2R 92/4885P2RX3 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.